OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update
September 26, 2024 12:00 ET
|
OSE Immunotherapeutics
OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update Financial and business highlights Total H1 2024 incomes of €82.5 million thanks to Company’s new...
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States
September 25, 2024 16:01 ET
|
NuCana plc
EDINBURGH, United Kingdom, Sept. 25, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced the issuance of a new patent by the United States Patent and Trademark Office (USPTO) covering...
Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab
September 24, 2024 23:29 ET
|
Junshi Biosciences
SHANGHAI, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to...
Renal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
September 24, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Renal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight ...
Transgene prévoit d’importants résultats cliniques d’ici fin 2024 et confirme sa visibilité financière jusqu’au 4ème trimestre 2025
September 24, 2024 11:45 ET
|
Transgene S.A.
Résultats financiers du 1er semestre 2024 et point sur l’activité Produit phare TG4050 (vaccin thérapeutique individualisé) : - Premiers signes de bénéfice clinique dans le cancer...
Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025
September 24, 2024 11:45 ET
|
Transgene S.A.
2024 Half-Year Results and Business Update Lead program TG4050 (individualized immunotherapy): – First signs of clinical benefit in adjuvant head and neck cancer reported at AACR 2024,...
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
September 24, 2024 03:00 ET
|
HUTCHMED (China) Limited
— Approval based on results from global Phase III FRESCO-2 trial in patients with previously treated metastatic colorectal cancer — — Fruquintinib already approved in several regions including the...
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
September 20, 2024 09:00 ET
|
FN Media Group LLC
PALM BEACH, Fla., Sept. 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer...
Merus gibt Annahme von Abstracts zur Präsentation auf dem ESMO Asia Congress 2024 bekannt
September 18, 2024 07:55 ET
|
Merus N.V.
UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, das Unternehmen, wir oder unser), ein Unternehmen für klinische Onkologie, das...
Merus annonce l'acceptation du résumé pour présentation lors du congrès de l’ESMO Asie 2024
September 18, 2024 07:55 ET
|
Merus N.V.
UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 18 sept. 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS) (Merus, la Société, nous, notre ou nos), une société du secteur de l’oncologie au stade...